Newcastle Confidence in Concept 2016
Lead Research Organisation:
Newcastle University
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Organisations
People |
ORCID iD |
Publications
Saint-Criq V
(2021)
Extracellular phosphate enhances the function of F508del-CFTR rescued by CFTR correctors.
in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Kurzawa-Akanbi M
(2021)
Age-related macular degeneration - biomarkers and therapies.
in Regenerative medicine
Gardner AI
(2021)
Interferon regulatory factor 8 regulates expression of acid ceramidase and infection susceptibility in cystic fibrosis.
in The Journal of biological chemistry
Malik TH
(2021)
Gain-of-function factor H-related 5 protein impairs glomerular complement regulation resulting in kidney damage.
in Proceedings of the National Academy of Sciences of the United States of America
Oxley A
(2021)
Determination of Vitamin A Total Body Stores in Children from Dried Serum Spots: Application in a Low- and Middle-Income Country Community Setting.
in The Journal of nutrition
Shaw L
(2021)
Purines for Rapid Identification of Stroke Mimics (PRISM): study protocol for a diagnostic accuracy study.
in Diagnostic and prognostic research
Kamala O
(2021)
Homodimeric Minimal Factor H: In Vivo Tracking and Extended Dosing Studies in Factor H Deficient Mice.
in Frontiers in immunology
Lumley HA
(2020)
A scoping review of pre-hospital technology to assist ambulance personnel with patient diagnosis or stratification during the emergency assessment of suspected stroke.
in BMC emergency medicine
Neal MA
(2020)
Dynamic susceptibility contrast 19 F-MRI of inhaled perfluoropropane: a novel approach to combined pulmonary ventilation and perfusion imaging.
in Magnetic resonance in medicine
| Description | A diagnostic accuracy study of portable EEG to triage acute stroke |
| Amount | £221,623 (GBP) |
| Organisation | Forest Devices (USA) |
| Sector | Private |
| Country | United States |
| Start | |
| Description | AuToDeCRA 2 - Matching physiology to function: study autologous tolerogenic dendritic cell therapy focus on delivery route |
| Amount | £1,106,921 (GBP) |
| Funding ID | 21811 |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2018 |
| End | 07/2022 |
| Description | Confidence in Concept 2018 - New tools to image pulmonary embolism without exposure to ionising radiation |
| Amount | £68,878 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 02/2021 |
| Description | Development of novel type I interferon inhibitors |
| Amount | £10,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2021 |
| Description | EPSRC Impact Accelerator Award |
| Amount | £45,000 (GBP) |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Investigating the antimicrobial activity of sphingoid bases as a novel therapy against respiratory infection in children |
| Amount | £181,792 (GBP) |
| Funding ID | BH181815 |
| Organisation | Newcastle upon Tyne Hospitals NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 03/2019 |
| End | 02/2021 |
| Description | Investigating the antimicrobial activity of sphingosine as a novel therapy against respiratory infection in children |
| Amount | £181,792 (GBP) |
| Organisation | Newcastle upon Tyne Hospitals NHS Charity |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Investigation of replapsed Burkitt lymphoma |
| Amount | £1,500 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Medimmune Grant |
| Amount | £20,000 (GBP) |
| Funding ID | 8300264934 |
| Organisation | AstraZeneca |
| Department | MedImmune |
| Sector | Private |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 05/2022 |
| Description | Microglia in the type I interferon system: protective and pathogenic mechanisms |
| Amount | £412,853 (GBP) |
| Funding ID | 211153 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 11/2021 |
| Description | PREMNEC: Preterm enteroids for determining the mechanism of necrotising enterocolitis |
| Amount | £161,574 (GBP) |
| Organisation | Marie Curie |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Personalised Therapies for all: Restoring airway function in CF using Alternative Chloride Channels |
| Amount | £750,000 (GBP) |
| Organisation | Cystic Fibrosis Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Precision medicine technologies: shaping the future - Point-of-care for stroke subtype diagnosis to enable rapid treatment |
| Amount | £939,000 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Process Control and Novel Materials for the Reactive Jet Impingement Process |
| Amount | £1,145,056 (GBP) |
| Funding ID | EP/V013092/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2021 |
| End | 09/2024 |
| Description | Purines for Rapid Identification of Stroke Mimics (PRISM) |
| Amount | £711,974 (GBP) |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Sir Henry Dale Fellowship |
| Amount | £995,985 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 12/2020 |
| Description | The role of tumour-infiltrating macrophages, dendritic cells, and T- regulatory cells in Classical Hodgkin lymphoma |
| Amount | £9,261 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Type 1 interferon in Zika virus neuropathy |
| Amount | £10,000 (GBP) |
| Organisation | British Medical Association (BMA) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | Understanding the Properdin Paradox using C3 D1115N (gain-of-function) knock-in mice |
| Amount | £569,241 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | Wellcome Trust ISSF - The role of tumour-infiltrating macrophages, dendritic cells, and T- regulatory cells in Classical Hodgkin lymphoma |
| Amount | £9,261 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | i4i Innovative diagnostic test for early stage, high risk, melanoma AMLo |
| Amount | £927,143 (GBP) |
| Funding ID | II-LA-0417-20001 |
| Organisation | National Institute for Health Research |
| Sector | Public |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 12/2020 |
| Title | MODIFIED COMPLEMENT PROTEINS AND USES THEREOF |
| Description | Certain embodiments of the present invention relate to regulation of the innate immune system and complement activation. In particular, but not exclusively certain embodiments relate to a complement regulator protein and pharmaceutical compositions thereof for use in the treatment of diseases associated with or mediated by the alternative complement pathway and methods of treating such diseases and other subject matter. |
| IP Reference | WO2018197873 |
| Protection | Patent application published |
| Year Protection Granted | 2018 |
| Licensed | No |
| Impact | It is hoped that this invention will make an impact in the field of kidney transplantation. |
| Company Name | AMLO BIOSCIENCES LIMITED |
| Description | Dedicated to providing a prognostic test for early AJCC Stage I and Stage II melanoma to better identify a patient's true risk of disease progression. |
| Year Established | 2017 |
| Impact | The company is developing prognostic tests,to help healthcare providers identify which patients are most at risk of melanoma disease progression. |
| Website | https://amlo-biosciences.com/ |